The pharmaceutical company is investing in a greenfield project as it looks to resolve ongoing FDA compliance issues at three existing Indian facilities.
The company opened a new site in India and expanded facilities in Korea and Singapore to support biologics, vaccine, and cell and gene therapy biomanufacturing.
